Immunovant/$IMVT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunovant
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Ticker
$IMVT
Sector
Primary listing
Employees
315
Headquarters
Website
Immunovant Metrics
BasicAdvanced
$6.9bn
-
-$2.77
0.70
-
Price and volume
Market cap
$6.9bn
Beta
0.7
52-week high
$36.29
52-week low
$14.32
Average daily volume
2.1m
Financial strength
Current ratio
9.086
Quick ratio
8.677
Total debt to equity
0.008
Profitability
EBITDA (TTM)
-532.493
Effective tax rate (TTM)
-0.04%
Management effectiveness
Return on assets (TTM)
-38.43%
Return on equity (TTM)
-64.82%
Valuation
Price to book
8
Price to tangible book (TTM)
8
Price to free cash flow (TTM)
-14.976
Free cash flow yield (TTM)
-6.68%
Free cash flow per share (TTM)
-2.233
Growth
Earnings per share change (TTM)
1.51%
3-year earnings per share growth (CAGR)
17.37%
What the Analysts think about Immunovant
Analyst ratings (Buy, Hold, Sell) for Immunovant stock.
Immunovant Financial Performance
Revenues and expenses
Immunovant Earnings Performance
Company profitability
Immunovant News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs